New antibiotic a possible alternative to treat Lyme disease
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
New dendritic hydrogels were tested against several infectious bacteria and could be used as an an antibiotic-free treatment in the future.
Researchers have created the first “living medicine” to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.
Lipophosphonoxins may represent the next generation of antibiotics and can be delivered using a new type of dressing for skin wounds.
A new ex vivo model treated animal wounds with mesenchymal stromal cells (MSCs) and reduced MRSA infection, expanding therapeutic options for humans.
New research has explored the role of nasal bacteria to better develop intranasal vaccines for viruses such as COVID-19 and flu.
Researchers have used comparative metabologenomics to uncover what may be “silencing” bacteria to produce desirable compounds.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
Researchers have developed a platform named FAST to produce antibiotics that specifically target just the bacteria of interest.
Scientists have discovered that manipulating residues enables precision during the antibiotic biosynthesis assembly line.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
This article introduces insights into combatting multidrug resistance via high-throughput laboratory evolution, pointing to the mechanisms of underlying evolved drug resistance.
New research has shown that 'hidden' lysis genes in bacteriophages could be used in the development of a new class of antibiotics.
In this article, Drug Target Review’s Hannah Balfour discusses three of the latest developments in imaging for disease research and drug development.
A single change to the structure of bacterial ribosomes prevents macrolide antibiotics from binding and killing the bacteria, according to a study.